Schrödinger, Inc. (NASDAQ:SDGR) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of Schrödinger, Inc. (NASDAQ:SDGR - Get Free Report) have received an average recommendation of "Moderate Buy" from the eleven analysts that are currently covering the company, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $32.90.

Separately, BMO Capital Markets raised their price target on shares of Schrödinger from $25.00 to $28.00 and gave the stock an "outperform" rating in a research report on Wednesday, November 13th.

Insider Activity

In other news, insider Margaret Dugan sold 1,531 shares of the stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $17.78, for a total transaction of $27,221.18. Following the sale, the insider now directly owns 13,469 shares of the company's stock, valued at $239,478.82. This represents a 10.21 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 8.60% of the company's stock.

Hedge Funds Weigh In On Schrödinger

A number of large investors have recently bought and sold shares of SDGR. GAMMA Investing LLC lifted its holdings in Schrödinger by 87.5% during the fourth quarter. GAMMA Investing LLC now owns 2,796 shares of the company's stock valued at $54,000 after purchasing an additional 1,305 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Schrödinger by 3.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 122,702 shares of the company's stock valued at $2,276,000 after buying an additional 4,403 shares in the last quarter. Geode Capital Management LLC lifted its stake in Schrödinger by 1.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,319,205 shares of the company's stock valued at $24,476,000 after buying an additional 24,114 shares in the last quarter. Barclays PLC boosted its holdings in Schrödinger by 421.6% in the 3rd quarter. Barclays PLC now owns 107,554 shares of the company's stock worth $1,995,000 after buying an additional 86,933 shares during the last quarter. Finally, State Street Corp increased its stake in Schrödinger by 1.8% during the 3rd quarter. State Street Corp now owns 2,155,620 shares of the company's stock worth $39,987,000 after buying an additional 38,972 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company's stock.

Schrödinger Trading Down 5.1 %

Shares of NASDAQ:SDGR traded down $1.04 on Friday, hitting $19.29. 515,545 shares of the company were exchanged, compared to its average volume of 577,956. The stock's 50 day moving average price is $20.43 and its 200 day moving average price is $20.01. Schrödinger has a 1-year low of $16.67 and a 1-year high of $33.63. The firm has a market capitalization of $1.41 billion, a P/E ratio of -8.24 and a beta of 1.59.

Schrödinger (NASDAQ:SDGR - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.52) EPS for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.12). Schrödinger had a negative return on equity of 35.77% and a negative net margin of 91.84%. The firm had revenue of $35.30 million for the quarter, compared to analyst estimates of $41.25 million. During the same period in the prior year, the firm posted ($0.86) EPS. The business's revenue was down 17.1% compared to the same quarter last year. On average, equities analysts predict that Schrödinger will post -2.29 EPS for the current fiscal year.

About Schrödinger

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.